01
BPC-157
Evidence maturity: limited human literature; preclinical work dominates.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
Evidence relationship explorer
Research evidence pathways map
Browse current Peptide Index evidence profiles and see which ones connect to a separately recorded published-study directory entry. A connection indicates shared source context only—it is not evidence of benefit, safety, quality, availability, or a personal-use decision.
13
evidence profiles
03
direct study links
03
study directory records
Profile sources only
02
TB-500
Evidence maturity: limited human data specific to TB-500; preclinical discussion dominates.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
03
CJC-1295
Evidence maturity: limited early human physiology evidence; long-term clinical outcomes remain unestablished.
04
Ipamorelin
Evidence maturity: limited human outcome evidence; preclinical and mechanism discussion dominates.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
05
Tesamorelin
Evidence maturity: established randomized-trial evidence for a specific regulated indication; not a general-purpose outcome claim.
06
GHK-Cu
Evidence maturity: limited human clinical literature; laboratory and preclinical evidence is more prominent.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
07
MOTS-c
Evidence maturity: preclinical research dominates; human intervention evidence remains limited.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
08
Kisspeptin
Evidence maturity: human physiological effects are studied; long-term clinical use and safety questions remain limited.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
09
AOD-9604
Evidence maturity: limited human development literature; no established general clinical use in this reference context.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
10
Follistatin
Evidence maturity: limited, disease-specific human research; healthy-population claims are not established.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
11
Retatrutide
Evidence maturity: phase 2 human trial evidence; long-term outcomes and regulatory status remain essential limits.
12
Semaglutide
Evidence maturity: extensive randomized-trial and regulated-product evidence for specific indications; not a substitute for individual clinical guidance.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
13
SS-31 / Elamipretide
Evidence maturity: early, disease-specific human trials and varied clinical research outcomes; not a general clinical-use conclusion.
Evidence profile
Open profile
Current limit
No matching controlled study-directory record is currently published in this map.
Scope note
A missing line is not a negative conclusion
This map is intentionally compact. A pathway is absent when the current controlled study directory does not include a direct matching record—not because the broader literature was exhaustively searched or because a compound has no research. Read each evidence profile’s cited sources and limitations for its distinct context.